Wealthgate Biotech Fund
Science as an Investment Thesis.
We invest in listed small- and mid-cap biotech companies where clinical catalysts, scientific diligence, and valuation dislocations create asymmetric return opportunities.
Sector overview
Why Biotech. Why now.
Structural tailwinds create a favorable environment for a selective, event-driven biotech strategy.
Biotechnology is one of the few areas where deep clinical diligence, precise catalyst timing, and valuation dislocations can still generate significant alpha. The fund is explicitly constructed around this inefficiency.
Investing with responsibility
Where returns and medical progress converge.
Wealthgate connects investment strategy with medical progress. Returns and scientific advancement are not contradictory.
Medical Progress
Medical progress emerges where mechanism of action, clinical design and endpoint structure align consistently. It is precisely in these setups that clinical risks can be better quantified and asymmetric opportunities identified.
Rare Diseases
Limited patient numbers require specialised development approaches. For focused biotech companies, attractive opportunities arise here – also as partners or acquisition targets for large pharmaceutical companies.
Immuno-Oncology Combination Therapies
While checkpoint inhibitors are established, the next wave of innovation lies in rationally designed combinations. Key factors here are mechanisms such as T-cell exhaustion, tumour microenvironment and biomarker selection – areas where differentiated clinical approaches can lead to clear outperformance.
Long-term Societal Impact
An investment approach that views returns and medical benefit not as a contradiction, but as a prerequisite.
Investment approach
A repeatable underwriting framework.
The core of our differentiation is not simple stock picking – but a documented process that translates science, study design, regulatory context, and market structure into a conviction score and ultimately a position size.
Our process
From idea to position – in five structured steps.
Screening
Liquid SMID biotech with upcoming catalysts
Asset Diligence
MOA, study design, endpoints, regulation, balance sheet
Matrix Scoring
Standardized evaluation across five pillars
Portfolio Action
Score → Conviction → Position size
Post-Catalyst Review
Continuous adjustment with new data
Screening
Liquid SMID biotech with upcoming catalysts
Asset Diligence
MOA, study design, endpoints, regulation, balance sheet
Matrix Scoring
Standardized evaluation across five pillars
Portfolio Action
Score → Conviction → Position size
Post-Catalyst Review
Continuous adjustment with new data
Sector overview
Biotech Catalyst Scoring Matrix
The heart of step 3: Every idea is deconstructed across four evaluation pillars. Positive factors increase expected return, negative ones cap conviction — before a position is sized.
Company Quality
Program Quality
Scientific Value
Trading Setup & Risk
KO Rules – Hard Exclusions
With ≥2 active KO triggers, conviction cannot remain high — regardless of the overall score.
What sets us apart
Four pillars of differentiation.
Our principles are integrated into the scoring logic and portfolio construction – and thus directly impact every investment decision.
Structured scientific diligence
Proprietary scoring framework that translates complex biotech catalysts into structured investment probabilities. Quantified evaluation across five pillars.
Focus on asymmetric catalysts
Targeted positioning ahead of clinical data releases and regulatory decisions where the risk-return profile shifts significantly.
Risk control through KO rules
Structural risks are systematically excluded through defined KO criteria – regardless of the attractiveness of individual factors.
Disciplined position sizing
High Conviction: 4–8%, Good Position: 2–4%, Small Tactical: 0.5–2%. Narrative alone never suffices for capital allocation.
Our focus topics.
Setup quality determines allocation – not rigid sector quotas. These indications show where we search for the best asymmetric opportunities.
Infectious Diseases
Antifungals, antivirals, resistance mechanisms. Growing importance through global health challenges.
Cardiovascular Diseases
Novel targets, lipid disorders. Leading cause of death worldwide with growing innovation potential.
Oncology
Targeted therapies, antibody-drug conjugates (ADCs), immuno-oncology. Largest indication field with high innovation density.
Metabolic Diseases
NASH/MASH, diabetes, specialty metabolics. Large unmet medical need with significant market potential.
Neurological Diseases
CNS disorders with measurable endpoints. Alzheimer’s, Parkinson’s, MS — high medical need amid demographic change.
Rare Diseases
Orphan drug development, gene therapy, enzyme replacement therapy. Increased approval probability.
Fund Data and Performance Overview
We combine our team’s expertise with sound market knowledge to provide our clients with a sustainable competitive advantage.
How the fund is structured
Concentrated in clinically advanced biotech companies with identifiable catalysts and clear underwriting cases
Leading Portfolio Positions
Several portfolio positions have become acquisition or licensing targets over time – an indicator that the process identifies companies with strategic value early.
Akero Therapeutics · Cidara Therapeutics · SpringWorks Therapeutics
Everything you need to know.
Dr. Lars Bohnert
Head of Life Science Investments, Fund Advisory Wealthgate Biotech Fund
Dr. med. Lars Bohnert bridges two worlds: clinical medicine and capital markets. As Head of Life Science Investments, he oversees the Wealthgate Biotech Fund and biotech investments. In parallel, he works as a physician across various internal medicine departments and brings experience from medical genetics. His first experience at the intersection of science and investment came as a Healthcare Analyst at one of Germany’s largest healthcare and biotech funds. This dual role is no coincidence: those who invest in biotechnology should be able to read clinical evidence – not just balance sheets.
„Conviction must be earned through evidence."
Get to know our Wealthgate Biotech Fund.
A personal conversation is the best first step.
Schedule a conversation